Dana Pizzuti - 01 Dec 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Med and Dev Officer
Signature: /s/ Tobin Schilke, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 01 Dec 2025
Net transactions value: -$140,650
Form type: 4
Filing time: 03 Dec 2025, 16:28:31 UTC
Previous filing: 05 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pizzuti Dana	Chief Med and Dev Officer	C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO	/s/ Tobin Schilke, as attorney-in-fact	03 Dec 2025	0001948238

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$84,450	+5,000	+7.5%	$16.89	71,837	01 Dec 2025	Direct	F1
transaction	CRNX	Common Stock	Sale	$225,100	-5,000	-7%	$45.02	66,837	01 Dec 2025	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-6.8%	$0.000000	69,042	01 Dec 2025	Common Stock	5,000	$16.89	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan.
F2	The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
F3	The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $45.02 per share. The range of sale prices on the transaction date was $44.59 to $45.51. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F4	The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.